Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values

International Journal of Colorectal Disease

Volumn 24, Issue 10, 2009, Pages 1157-1167

  Mäkitalo, Laura ^a   Sipponen, Taina ^a   Kärkkäinen, Päivi ^a   Kolho, Kaija Leena ^b   Saarialho Kere, Ulpu ^a,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Calprotectin; CDAI; CDEIS; Infliximab; MMP 26

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; GELATINASE B; INFLIXIMAB; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 26; METHOTREXATE; PREDNISONE; STEROID; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DOWN REGULATION; ENDOSCOPY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE CELL; MACROPHAGE; MALE; NEUTROPHIL; PRIORITY JOURNAL; STROMA CELL;

ADULT; CROHN DISEASE; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; STROMAL CELLS; TISSUE INHIBITOR OF METALLOPROTEINASES; YOUNG ADULT;

EID: 69849103201     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-009-0756-5     Document Type: Article

References (47)

1. Shanahan F (2002) Crohn's disease. Lancet 359:62-69
2. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417-429
3. Taylor CT, Keely SJ (2007) The autonomic nervous system and inflammatory bowel disease. Auton Neurosci 133:104-114
4. Parks WC, Wilson CL, López-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617-629
5. Ravi A, Garg P, Sitaraman SV (2007) Matrix metalloproteinases in inflammatory bowel disease: Boon or a bane? Inflamm Bowel Dis 13:97-107
6. Saarialho-Kere UK, Vaalamo M, Puolakkainen P et al (1996) Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 148:519-526
7. Heuschkel RB, MacDonald TT, Monteleone G et al (2000) Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 47:57-62
8. Kirkegaard T, Hansen A, Bruun E et al (2004) Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 53:701-709
9. Warnaar N, Hofker HS, Maathuis MH et al (2006) Matrix metalloproteinases as profibrotic factors in terminal ileum in Crohn's disease. Inflamm Bowel Dis 12:863-869
10. Bailey CJ, Hembry RM, Alexander A et al (1994) Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 47:113-116
11. Baugh MD, Perry MJ, Hollander AP et al (1999) Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117:814-822
12. Stumpf M, Cao W, Klinge U et al (2005) Reduced expression of collagen type I and increased expression of matrix metalloproteinases 1 in patients with Crohn's disease. J Invest Surg 18:33-38
13. Srivastava MD, Kulaylat MN (2004) Gene expression profiles of late colonic Crohn's disease. J Med 35:233-255
14. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P et al (1998) Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 152:1005-1014
15. Gill SE, Parks WC (2008) Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 40:1334-1347
16. Bister VO, Salmela MT, Karjalainen-Lindsberg ML et al (2004) Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig Dis Sci 49:653-661
17. Pender SL, Li CK, Sabatino AD et al (2006) Role of macrophage metalloelastase in gut inflammation. Ann N Y Acad Sci 1072:386-388
18. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA et al (2007) Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 13:2960-2966
19. Mary JY, Modigliani R (1989) Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30:983-989
20. Best WR, Becktel JM, Singleton JW et al (1976) Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70:439-444
21. Sostegni R, Daperno M, Scaglione N et al (2003) Review article: Crohn's disease: Monitoring disease activity. Aliment Pharmacol Ther 17:11-17
22. Sipponen T, Savilahti E, Kolho KL et al (2008) Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 14:40-46
23. D'Haens GR, Geboes K, Peeters M et al (1998) Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114:262-267
24. Kolho KL, Raivio T, Lindahl H et al (2006) Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 41:720-725
25. von Roon AC, Karamountzos L, Purkayastha S et al (2007) Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 102:803-813
26. Bister V, Mäkitalo L, Jeskanen L et al (2007) Expression of MMP-9, MMP-10 and TNF-alpha and lack of epithelial MMP-1 and MMP-26 characterize pyoderma gangrenosum. J Cutan Pathol 34:889-898
27. Impola U, Jeskanen L, Ravanti L et al (2005) Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol 152:720-726
28. Kuivanen T, Jeskanen L, Kyllönen L et al (2006) Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13 are present in epithelial cells of keratoacanthomas. Mod Pathol 19:1203-1212
29. Isaka K, Nishi H, Nakai H et al (2003) Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer 97:79-89
30. Salmela MT, MacDonald TT, Black D et al (2002) Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: Analysis by gene array and in situ hybridisation. Gut 51:540-547
31. Manfredi MA, Zurakowski D, Rufo PA et al (2008) Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 14:1091-1096
32. Gao Q, Meijer MJ, Schluter UG et al (2007) Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 13:693-702
33. Meijer MJ, Mieremet-Ooms MA, van Duijn W et al (2007) Effect of the anti-tumor necrosis factor- alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis 13:200-210
34. Cordiali-Fei P, Trento E, D'Agosto G et al (2007) Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann N Y Acad Sci 1110:578-589
35. Klimiuk PA, Sierakowski S, Domyslawska I et al (2004) Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 31:238-242
36. Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942-2953
37. Marchenko GN, Ratnikov BI, Rozanov DV et al (2001) Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 356:705-718
38. Uría JA, López-Otín C (2000) Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 60:4745-4751
39. Li W, Savinov AY, Rozanov DV et al (2004) Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin. Cancer Res 64:8657-8665
40. Bister V, Salmela MT, Heikkilä P et al (2005) Matrilysins-1 and -2 (MMP-7 and -26) and metalloelastase (MMP-12), unlike MMP-19, are up-regulated in necrotizing enterocolitis. J Pediatr Gastroenterol Nutr 40:60-66
41. Matsuno K, Adachi Y, Yamamoto H et al (2003) The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol 38:348-354
42. McKaig BC, McWilliams D, Watson SA et al (2003) Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 162:1355-1360
43. Stallmach A, Giese T, Schmidt C et al (2004) Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 19:308-315
44. Schmidt C, Giese T, Hermann E et al (2007) Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis 13(1):65-70
45. Di Sabatino A, Pender SL, Jackson CL et al (2007) Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 133:137-149
46. Sipponen T, Savilahti E, Kärkkäinen P et al (2008) Fecal calprotectin, lactoferrin and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 14:1392-1398
47. Isaksen B, Fagerhol MK (2001) Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. Mol Pathol 54:289-292